To provide bispecific antibodies and highly functional bispecific antibodies, which are produced by using a new anti-human EGF receptor 1 (Her 1) antibody different from the antibody 528. A bispecific antibody, comprising a variable region of the light chain (2L: SEQ ID NO:2) and a variable region of the heavy chain (2H: SEQ ID NO:4) of an anti-human EGF receptor 1 antibody 225, and a humanized variable region of the light chain (OL: SEQ ID NO:6) and a humanized variable region of the heavy chain (OH: SEQ ID NO:8) of an anti-CD3 antibody OKT, and the like.